Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2025-11-12 Earnings Release
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding an upgrade to the company's full-year financial outlook. It provides key highlights of the revised guidance (revenue growth and EBIT margin) but explicitly states that the full Q3 report will be published later. According to the 'Menu vs Meal' rule, since this is an announcement of financial performance updates rather than the full financial report itself, and it functions as a regulatory disclosure of inside information, it is classified as an Earnings Release (ER). Q3 2025
2025-11-12 English
M&A Activity 2025
M&A Activity Classification · 100% confidence The document is a formal corporate announcement regarding a new strategic partnership between ALK and GenSci for the Chinese market. It details the financial terms (upfront and milestone payments), the scope of the partnership, and the strategic rationale. This type of announcement, which discloses material information to the market, is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A (which usually refers to corporate takeovers/mergers of the company itself) or Earnings Releases.
2025-09-17 Danish
M&A Activity 2025
M&A Activity Classification · 100% confidence The document is a corporate announcement regarding a new partnership agreement between ALK and GenSci. It details the financial terms, strategic goals, and operational changes resulting from this partnership. While it contains significant information, it is structured as a press release/regulatory announcement (indicated by the 'Intern viden' header and the 'Selskabsmeddelelse' reference). It does not fit into specific categories like 10-K, IR, or CT, and it is not merely a notification of a report publication, but rather the announcement of a material business event. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-17 Danish
M&A Activity 2025
M&A Activity Classification · 100% confidence The document is a corporate announcement regarding a strategic partnership and licensing agreement between ALK and GenSci to expand into the Chinese market. It details the financial terms, including upfront and milestone payments, and the operational impact of the deal. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary regulatory announcement rather than just a notification of a report. Given that it describes a significant business development and partnership, it falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like M&A (which usually implies a takeover or merger of the company itself) or other specialized financial reports.
2025-09-17 English
M&A Activity 2025
M&A Activity Classification · 100% confidence The document is a corporate announcement regarding a strategic partnership and licensing agreement between ALK and GenSci. It details the financial terms, including upfront and milestone payments, and the strategic rationale for the deal. This type of announcement, which details a specific business transaction or partnership, is best classified as a Regulatory Filing (RNS) as it is a public disclosure of inside information under the EU Market Abuse Regulation, and does not fit into more specific categories like M&A (which usually implies a takeover or merger of entities) or Capital/Financing updates.
2025-09-17 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Six-month interim report (Q2) 2025' and contains detailed financial highlights, revenue data, EBIT margins, and management commentary regarding performance. Although it mentions an attachment at the end, the text itself provides the substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report rather than just an announcement. H1 2025
2025-08-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.